Microbiome-optimized autologous stem cell therapy (Biotech Holdings)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMicrobiome-optimized autologous stem cell therapy (Biotech Holdings)
Drug Alias NameAutologous stem cell therapy - Biotech HoldingsProCell activated stem cells - Biotech Holdings
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy
Mechanisms of ActionCell replacementsHepatocyte growth factor modulatorsRegulatory T-lymphocytes stimulants +[4] 
TargetsHepatocyte growth factor
Therapy Area/IndicationsPeripheral Vascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesBiotech Holdings
China Registration ClassN/A

Develop Information

Active CompaniesBiotech Holdings
Inactive CompaniesN/A
Active IndicationsPeripheral Vascular Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A